The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Chime Biologics, a global CDMO, and Mabgeek, a clinical-stage innovative antibody drug development biotech, have successfully ...

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, has appointed Lori ...

Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...

Veeda Group has unveiled a new logo and brand identity— Veeda Lifesciences —reflecting the brand’s evolution from a ...

Sangamo plans to explore all options to commercialize the Hemophilia A asset.

Demonstrates its commitment to providing quality, cost-saving treatment options to clinicians and the patients they serve.

LGM Pharma’s chief executive talks industry trends and the company’s continued growth as a provider of tailored API and CDMO services. Contract Pharma is the premier media outlet linking contract ...

Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.

Integration of Ori's IRO Platform with Cue and Lovo processing systems aims to enhance efficiency in CGT manufacturing.

The acquisition is expected to be completed in the coming days.

Novo Nordisk will soon acquire from Novo Holdings Catalent’s three fill-finish sites located in Italy, the U.S., and Belgium.